UBS group ceases substantial holding in Mayne Pharma

UBS Group AG and its related bodies corporate ceased to be a substantial holder in Mayne Pharma Group Limited on October 16, 2025. This follows a previous notice given to the company on August 15, 2025.

The cessation involved numerous transactions between August 15, 2025, and October 16, 2025, with both buy and sell orders executed by UBS Securities Australia Ltd. Significant activities on the final day, October 16, 2025, included substantial sell orders totaling AU$1,369,545 (217,426 ordinary shares), AU$1,309,436 (207,646 ordinary shares), and AU$1,049,756 (166,517 ordinary shares). Conversely, large buy orders were also recorded on the same day, such as AU$1,414,554 (224,675 ordinary shares) and AU$1,156,147 (183,396 ordinary shares).

These transactions represent a complete divestment of UBS Group AG's substantial holding. The report did not indicate any changes in association for the substantial holder. The notice was signed by Ruby Ko and Dominic Eichrodt, both authorised signatories, on October 20, 2025.